LOOKING FOR RESEARCH FUNDING
- At Breakthrough Cancer Research we fund researchers with projects which aim to improve cancer care and survival. We favour funding ideas which are patient focused and/or clinically linked and translationally oriented. We look for projects which fulfil our current research priorities. Bench projects are considered but should a have clear path to translation, however long, and researchers should be clear on the unmet need or clinical challenge the project seeks to address.
- We fund in a variety of ways including through our own fellowships and scholarships and also through join funding and partnership schemes such as the HRCI-HRB Joint Funding Scheme and the Irish Research Councils Enterprise partnerships.
- Additionally, individual projects grants can be sought and the process is different depending on the level of funding sought. The Scientific Advisory Board discuss potential awards at various intervals during the year so it is advised to make informal inquiries before applying to firstname.lastname@example.org.
The All-Ireland – Cancer Network (AllCaN) Programme Grant is a new Breakthrough Cancer Research funding programme. This Programme Grant will fund networks of the best scientists/researchers at institutions across the Island of Ireland, to develop new and innovative approaches to improving cancer outcomes. Researchers will collaborate across disciplines, institutions, and as appropriate across the four pillars of prevention, detection, treatment and survivorship. The successful researchers will work together on a common goal, pooling their knowledge and resources to work together to eliminate barriers and to hasten the progression needed to improve patient outcomes.
One network will be funded to up to €1,000,000 for a maximum of 3 to 4 years
|Programme Launch||27th April 2022|
|Informal Inquiries||27th April – 2nd June 2022|
|Deadline for Expression of Interest||3rd June 2022, 12:00 Local time|
|Notification of successful teams for full applications||30th June 2022, 12:00 Local time|
|Deadline for submission of full proposals||12th September 2022, 13:00 Local time|
|Interviews of successful teams & Formal Offer||September/October 2022|
|Programme commences||January 2023|
Related Documents - Programme Guidelines and Application Instructions
Applied Partnership Awards 2022
Breakthrough are inviting researchers to submit proposals for the HRB Applied Partnership Awards (APA) addressing specific needs in poor prognosis cancers.
The scope for this funding call is;
- Improving early detection or treatment of pancreatic cancer. Pancreatic cancer survival rate is approximately 10%. There is a need for more research to increase the number of people surviving a pancreatic cancer diagnosis. Breakthrough are calling for proposals to address this need.
- The genetic aetiology of ovarian or uterine cancer (A combined call with the Emer Casey Foundation and Breakthrough Cancer Research). Compared to 7 other high income countries, Ireland had the worse ovarian cancer survival. We need more research to increase our understanding of the genetic aetiology of ovarian or uterine cancer beyond BRACA and Lynch syndrome, towards an earlier diagnosis and better treatments. Breakthrough and the Emer Casey Foundation together are calling for proposals to address this need.
The Applied Partnership Awards are designed to bring knowledge users and researchers together to develop research projects that address a specific need within the Irish health or social care system. Research findings will have a direct impact on decision-making in the knowledge user organisation.
This is a rolling call and as such there will be one round launched in 2022 with two separate closing dates and associated peer review cycles. The closing date for Cycle 1 is 27 April 2022. The closing date for Cycle 2 is 1 February 2023.
For more information on eligibility, please see the link below.
Please submit a 1 page proposal, with the research title, the need being addressed, the team, the method of addressing the need, and proposed budget to email@example.com by March 10th 2022.
|Announcement||24th January 2022|
|Informal Inquiries||24th January – 10th March 2022|
|Deadline for Expression of Interest||10th March 2022|
|Deadline for submission of applications Time||27th April 2022|
Related documents to download:
The Musgrave Cancer Research PhD Scholarship in association with Breakthrough Cancer Research represents a successful partnership to fund world class cancer research in Ireland while educating the next generation of cancer research leaders. Two PhD Scholarships spanning 3 or 4 years are available, to take place at any University in the Republic of Ireland currently engaged in cancer research.
This call is open to researchers in Clinical, Biological, Epidemiologic, or Public Health fields. However, the proposal must be patient-focused with the ultimate aim of improving cancer care and increasing survival, and to fit with Breakthrough’s research priorities.
Applications will be limited to those focused on pancreatic, oesophageal, ovarian, lung, brain or liver cancer only.
|Scholarship Announcement||25th February 2022|
|Informal Inquiries||8th April 2022|
|Deadline for submission of applications||11th April 2022 13:00 (Irish Time)|
|Interviews (Zoom may be used)||Late May/Early June 2022|
|Scholarship Commences||September/October 2022|
Related Documents to Download
The 2022 Breakthrough Cancer Research Summer Student Scholarship is now opened. This programme is an initiative to facilitate the partnership of students with research teams and to foster the education of the next generation of cancer research leaders. Funding will be provided for 4 individual Scholarships, for the period of 6-10 week and to the value of €2,500 each.
The scholarships are to take place at any University in Ireland currently engaged in cancer research. It is open to researchers in Clinical, Biological, Epidemiologic, Public Health or Allied health fields.
Proposals must fulfil our research priorities, be patient-focused, with the ultimate aim to improve cancer care and increase survival.
|Scholarship Announcement||6th January 2022|
|Informal Inquiries||6th January – 1st March 2022|
|Deadline for submission of applications||4th March 2022 17:00 (GMT)|
|Interviews (Zoom Maybe used)||April/May 2022|
|Scholarship Commences||June 2022|
Related Documents to download:
Breakthrough Cancer Research are partners in the Irish Research Council’s (IRC) Enterprise Partnership Scheme (EPS).
The IRC EPS is a unique national initiative linking excellent researchers in all disciplines to enterprise; in the context of this call, enterprise partners can range from multinational corporations to SMEs, non-governmental organisations, and, where justified, public sector agencies. The scheme provides researchers with the opportunity to pursue research in collaboration with enterprise while based at an eligible higher education institution.
Through this co-funded programme, postgraduate researchers develop new, advanced knowledge and skills linked with industry and employer needs. The programme trains early-career researchers for the diversity of employment opportunities in industry, the public sector and the non-government sectors. For the enterprise partner, the scheme provides a low-risk, flexible route to research talent and innovation in an area closely aligned with its strategic interests.
With consideration to national and global challenges, the involvement of those organisations, both large and small, who seek technological, social and sustainable solutions and opportunities for people and planet is welcomed.
Breakthrough Cancer Research are open to applications as partners in the Irish Research Council (IRC) New Foundations Funding Programme 2022. Applications must align with Breakthrough Research Priorities
New Foundations is a key driver in progressing the IRC strategic priorities by enabling awardees to pursue research, networking or dissemination activities within and across the diversity of disciplines. The scheme provides support for:
- research actions;
- the development of networks and consortia;
- conference and workshop development; and
- capacity building for interdisciplinary collaboration.
Since 2015, over 200 community, voluntary and charity organisations have engaged across our programmes with 278 funded projects and an associated investment in excess of €6.5 million. Through partnerships with researchers, diverse community organisations can bring new evidence and insights to enhance their services and impact for those that need them. The scheme also includes strands supported by government departments and agencies. In each of the past three years, a dedicated strand of the call has provided opportunities for researchers to work on important areas of policy, including global development, crime, creativity and children.
|Call open||10 May 2022 at 4pm (Irish time)|
|FAQ deadline||14 June 2022 at 4pm (Irish time)|
|Applicant deadline||21 June 2022 at 4pm (Irish time)|
|Endorsement deadline||05 July 2022 at 4pm (Irish time)|
|Project start date||01 November 2022|
The Health Research Chairties Group (formerly MRCG) comprises over 40 charities. Some of these participate in the HRCI/HRB Joint Funding Scheme. The scheme funds internationally competitive and innovative research in areas of strategic relevance to particular HRCI-registered research charities.
The 2022 Call is now OPEN
INCREASING SURVIVAL OF PATIENTS WITH POOR PROGNOSIS CANCERS
Opening Date: 6th August 2021
Closing Date for EOI: 6th September 2021, 17:00 (GMT)
Closing Date for Full application: 18th October 2021, 17:00 (GMT)
Breakthrough Cancer Research is an Irish Medical Cancer Research Charity focused on funding research leading to new treatments for cancers which do not respond or are poorly served by available treatments. Breakthrough is committed to funding research to improve cancer care and outcomes and we ensure patient benefit is at the core of our efforts. We emphasise clinically engaged projects, throughout the patient journey which will positively impact survival of patients with the toughest to cure cancers.
Both scientific and patient public initiative (PPI) reviewers will contribute to the overall scoring of the applications and awarding of the grants. The PPI reviewers will assign a grade relating to appropriateness of the PPI involvement in the proposed research. When preparing your applications please consider, for example; (i) what PPI involvement do you have on your scientific and/or management teams, (ii) how have PPI members have contributed to the study design, preparation of the proposal, and (iii) what is your budget for PPI. If you have any questions, please contact us.
Breakthrough invite research applications which:
- Are patient focused and respond to an unmet clinical need in Pancreatic, Lung, Brain, Blood, Liver or Paediatric cancers only
- Can demonstrate a path to translation into an intervention/treatment (even if over longer term)
- Align with our Strategic Research Priorities
Please submit an EOI (2-3 pages max) to firstname.lastname@example.org by 5pm GMT on Monday 6th September 2021.
Following review by our Scientific Advisory Committee, a shortlist of successful applicants will be notified for requests for their full application.
Applicants invited to submit a full application will be provided with all relevant documentation.
Documentation including the full application form from previous rounds of the scheme can be found at www.hrb.ie.
For further information on HRCI-HRB Joint Funding Scheme go to:
- HRCI – https://hrci.ie/joint-funding-scheme/
- HRB – https://www.hrb.ie/funding/funding-schemes/all-funding-schemes/grant/hrcihrb-joint-funding-scheme-2020-previously-mrcg-hrb/
Funding of up to €300,000 will be provided, for projects from 12 up to 36 months.
|Expression of Interest Applications Open||6th August 2021|
|Deadline for Submission of EOI to Breakthrough Cancer Research||6th September 2021 17:00 GMT|
|Deadline for Submission of Full Applications to Breakthrough Cancer Research||18th October 2021 17:00 GMT|
|Charity Peer Review||November 2021 – Mid-January 2022|
|Right to Reply Phase||Mid-Late January 2022|
|Submission of Shortlisted applications to HRB||Early March 2022|
|HRB Board Meeting||June 2022|
|Applicant Notification||July 2020|
|Research Project Start||October 2022|
Related Documents to Download: ( B1 application form )
Breakthough Cancer Research, in partnership with ‘5 For The Fight’ is committed to investing in research which harnesses the immune system in the fight against cancer. We are also committed to identifying and supporting future research leaders in translational cancer research. The purpose of this fellowship is to fund two excellent cancer immunology scientific research projects which show the promise of impact for cancer patients.
The former Chairman of Qualtrics EMEA, Dermot Costello, who was first diagnosed with stage four colorectal cancer in 2014, used the last months of his illness to kick-start ‘5 For The Fight’ in Ireland and Europe. The ‘5 For The Fight’ campaign raises funds for cancer research to improve the outcome for patients. Breakthrough Cancer Research is the chosen partner of Qualtrics and ‘5 For The Fight’.
Breakthrough and ‘5 For The Fight’ are pleased to announce the second round of the Cancer Immunology Research Fellowship (CIRF) to the value of €300,000 each to support two excellent early/mid-career-stage investigators to carry out independent research for a three-year period to harness the immune system to treat poor prognosis and advanced cancers.
|Fellowship Announcement||13th August 2021|
|Informal Inquiries||13th August – 13th September 2021|
|Expression of Interest||13th September 2021, 17:00 GMT|
|Deadline for submission of proposals||11th October 2021, GMT|
|Short-listed Applicants informed||November 2021|
|Interviews & Formal Offer||December 2021|